By Melane Sampson
PetVivo Holdings (PetVivo Animal Health) (OTCQX: PTEV; OTCID: PETVW) is adapting human regenerative therapies for the management of osteoarthritis (OA) and other joint disorders in companion and athlete animals. The company’s proprietary platform includes a pipeline of biomaterial-based products highlighted by its breakthrough intra-articular injectable veterinary medical device—Spryng with OsteoCushion Technology.
“PetVivo’s origins lie in developing long-term implantable biomaterials for human medicine. Through that process, we discovered the tremendous advantages of designing biocompatible materials that replicate the body’s own tissue properties. By mimicking the native extracellular environment, our implants integrate naturally, minimizing inflammation and adverse reactions,” John Lai, CEO of PetVivo, says in an interview with BioTuesdays.
“This discovery led to our proprietary biomatrix microparticles—now the foundation of Spryng—which combine elasticity, durability, and biocompatibility to restore comfort and mobility in animals with OA,” he adds.
Mr. Lai explains that Spryng is an injectable dispersion of collagen-elastin hydrogel microparticles engineered to form a bio-integrative scaffold within the joint. The microparticles combine two purified, naturally derived proteins—bovine collagen and elastin—with a glycosaminoglycan (porcine heparin glycan). These components self-assemble into a sterile hydrated biomaterial that mimics the properties of natural cartilage and extracellular matrix, providing cushioning and joint support.
PetVivo’s technology originated in extensive human clinical research. In a 145-patient U.S. study across five sites, the biomatrix particles were used as dermal fillers with minimal immune response. “About 80% of participants preferred our product over the standard of care because it felt more natural and lasted longer,” Mr. Lai says.
He clarifies that after the material received FDA classification as a human medical device, PetVivo redirected its focus toward the rapidly growing $39.8-billion companion animal and equine market, applying the same biomaterials to address osteoarthritis and mobility disorders in pets and performance animals.
Introduced commercially to veterinarians in 2021, Spryng with OsteoCushion Technology is a veterinarian-administered intra-articular injection that helps restore joint function and mobility in dogs, cats, and horses suffering from OA and other joint related conditions. Composed of purified collagen, elastin, and a carbohydrate, Spryng mimics extracellular matrix composition and supports the restoration of diseased synovial tissue—improving biomechanics and joint stability.
“Spryng targets the mechanical cause of OA, not just the symptoms,” Mr. Lai contends. “Conventional treatments—NSAIDs, steroids, or monoclonal antibodies—merely mask pain and can actually accelerate joint damage as animals overexert themselves. Spryng works mechanically, avoiding the severe side effects seen in some biologic therapies, such as ataxia or seizures.”
“We’ve seen numerous cases where dogs scheduled for euthanasia received Spryng and went on to enjoy two or more years of active, pain-reduced life,” he adds.
According to Mr. Lai, Spryng has rapidly gained recognition among veterinarians and key opinion leaders. Dr. Tamara Grubb, DVM, PhD, DACVAA, highlighted Spryng in a peer-reviewed article in Veterinary Practice Today, recommending it as a first-line therapy because of its safety, efficacy, and cost advantages. Dr. Grubb later became president of the International Veterinary Academy of Pain Management.
He points out that in the equine sector, regulatory changes have also fueled adoption. The Horse Integrity and Safety Authority recently restricted competition for animals injected with hydrogel-based joint products for six months but specifically allowed Spryng under a two-week restriction, making it the only hydrogel alternative permitted for racing horses under that timeframe.
To date, more than 12,000 animals—including dogs, cats, and horses—have been treated with Spryng, supported by ongoing clinical and real-world studies. “In one canine study on hip osteoarthritis, Spryng improved mobility and reduced pain by more than 80%, outperforming other available therapies,” Mr. Lai asserts.
Given that OA affects up to 80% of dogs over age eight—approximately 66 million pets in the U.S.—Mr. Lai notes that Spryng presents an affordable and durable alternative to chronic drug regimens that can exceed $150 per month. The product is a single, long-lasting procedure that may be eligible for pet insurance coverage.
PetVivo’s products are manufactured using U.S.-sourced natural materials in its ISO 7/8-certified facility, capable of producing 5,000 syringes per month, scalable to 100,000 annually. The company holds 12 patents and six proprietary trade secrets protecting its biomaterials, processes, and applications.
Mr. Lai mentions that PetVivo’s distribution now spans the top six U.S. veterinary distributors, with recent expansion into Mexico and the UK, and regulatory clearance anticipated for the EU and Canada by 2026–2027.
The company’s second leading product, PrecisePRP, is the first FDA-reviewed platelet-rich plasma (PRP) product for safety and the only off-the-shelf, leucoreduced, allogenic PRP product on the market. Designed for intra-articular use in dogs and horses, PrecisePRP requires no blood draw or centrifuge, offering immediate, consistent results.
“The advantage is convenience and efficacy,” Mr. Lai says. “Traditional PRP requires costly equipment. Our freeze-dried PRP delivers high platelet concentrations and instant usability.”
He adds that beyond joint repair, PrecisePRP is showing potential in wound healing, regenerative medicine, and post-surgical recovery, which PetVivo plans to pursue as adoption broadens.
In October 2025, PetVivo entered a 10-year exclusive licensing agreement with closely held Digital Landia Holding to integrate its AgenticPet AI technology into veterinary marketing and engagement platforms.
“The AgenticPet AI platform tackles two critical challenges—high client acquisition costs and engagement with the Gen Z pet parent demographic,” Mr. Lai says. “It can cut acquisition costs from $50–$150 to as little as $1.50–$5.00 per client, while giving clinics direct access to digital-savvy pet owners.”
With Gen Z and Millennials now comprising 57% of U.S. pet parents, Mr. Lai emphasizes the importance of modern digital outreach. “Most veterinarians still rely on traditional marketing. Our AI partnership bridges that gap—bringing 21st-century efficiency to an industry ready for transformation.”
As the pet health market continues to evolve—with increasing insurance adoption and demand for natural, preventive care—PetVivo is collaborating with insurers to recognize Spryng and PrecisePRP as cost-saving interventions that may reduce the need for surgery.
In addition to OA, PetVivo’s research pipeline includes canine urinary incontinence, where early case studies show a six-fold increase in sphincter strength, and equine digital cushion augmentation, initially conducted by Dr. Tracy Turner, PetVivo advisory board member and current president of the American Equine Practitioners Association.
“With our experienced leadership, expanding IP portfolio, and growing international reach, PetVivo is poised to redefine joint care for companion and performance animals,” Mr. Lai concludes. “We’re not just treating symptoms—we’re helping restore mobility, vitality, and quality of life.”
• • • • •
To connect with PetVivo or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
